For the Inventor, By the Inventor

Enter assignee name

San Carlos, CA, United States of America

Incelldx, Inc.

USPTO Granted Patents = 16

EPO Patents = 3

Trademarks = 6

Forward Citations = 22

Loading Chart...

Loading Chart...

12 inventors (with patents filed for the assignee):

Bruce K Patterson (14 out of 25 patents)

Amanda Noel Chargin (6 out of 6 patents)

Edgar B Francisco (5 out of 5 patents)

4. Amruta Pise (5 out of 5 patents)

5. Keith Shults (5 out of 8 patents)

6. Hallison Rodrigues (3 out of 3 patents)

7. Emily Long (2 out of 2 patents)

8. Seyedhamed Jafarianmohamady (2 out of 2 patents)

9. Fangfang Yin (1 out of 1 patent)

10. Min Song (1 out of 1 patent)

11. Srividyabhuvaneswari Subramaniam (1 out of 1 patent)

12. Grace Elaine Knutson (1 out of 1 patent)

16 patents: Sort by Forward Citations

1. 12298309 - Methods of assaying neoplastic and neoplasia-related cells and uses thereof (2025-05-13),

2. 12228580 - Methods of assigning a COVID pathological type based on a cytokine/chemokine panel (2025-02-18),

3. 11988658 - Methods of assessing cellular breast samples and compositions for use in practicing the same (2024-05-21),

4. 11952373 - Method of treating hypercytokinemia by administering the CCR5/CCL5 (RANTES) interaction inhibitor maraviroc (2024-04-09),

5. 11726089 - Methods of assaying neoplastic and neoplasia-related cells and uses thereof (2023-08-15),

6. 11629196 - Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions (2023-04-18),

7. 11402391 - Methods of treating a long-hauler subject for chronic COVID-19 by administering a CCR5 or CCL5 antagonist (2022-08-02),

8. 11180491 - Method of treating COVID-19 by administering the CCR5/CCL5 (RANTES) interaction inhibitor maraviroc (2021-11-23),

9. 10782298 - Methods of detecting per cell PD-L1 expression and uses thereof (2020-09-22),

10. 10627389 - Methods of assessing cellular breast samples and compositions for use in practicing the same (2020-04-21),

11. 10308990 - Methods of evaluating a cellular sample for latent cellular replication competent HIV-1 (2019-06-04),

12. 10167526 - Methods and systems for predicting whether a subject has a cervical intraepithelial neoplasia (CIN) lesion from a suspension sample of cervical cells (2019-01-01),

13. 10011884 - Methods and systems for predicting whether a subject has a cervical intraepithelial neoplasia (CIN) lesion from a suspension sample of cervical cells (2018-07-03),

14. 9464332 - HPV E6, E7 MRNA assay and methods of use thereof (2016-10-11),

15. 8653250 - HPV E6, E7 MRNA assay and methods of use thereof (2014-02-18),

IncellDx, Inc. is a biotechnology company that specializes in the development and commercialization of novel cell-based diagnostics. They provide tools and services for single-cell analysis, biomarker discovery, and molecular diagnostics across various research and clinical applications. IncellDx's innovative technologies enable the identification and characterization of rare cells, gene expression profiling, and genotyping, thus empowering researchers and clinicians to gain valuable insights for precision diagnostics and personalized medicine.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

16 Patents

#23 in San Carlos, CA

#4,622 in California

#19,269 in US

#36,651 in the World

San Carlos, CA, United States of America

Incelldx, Inc.

Forward Citations = 22

12 inventors:

Bruce K Patterson (14 out of 25 patents)

Amanda Noel Chargin (6 out of 6 patents)

Edgar B Francisco (5 out of 5 patents)

4. Amruta Pise (5 out of 5 patents)

5. Keith Shults (5 out of 8 patents)

Please report any incorrect information to support@idiyas.com

Loading…